Immunosuppressive anti-TNFα therapy in humans is linked to a higher susceptibility for an infection with Leishmania or a reactivation of latent leishmaniasis (16–23), including reports that suggest differences in parasite control depending on the type of TNFα blocker applied (24–26). The gene discussed is TNF; the disease is infection.